ArticleInternational journal of urology : official journal of the Japanese Urological Association2026
Integrating Molecular Classification Based on FGFR3, KRAS, HRAS, and TP53 Mutation With TNM Staging Modestly Improves Prediction of Prognosis of Upper Tract Urothelial Carcinoma After Surgery.
Article in International journal of urology : official journal of the Japanese Urological Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeTo evaluate whether a simplified mutation-based classification using archival formalin-fixed paraffin-embedded (FFPE) specimens provides prognostic information beyond pathological stage in patients with upper tract urothelial carcinoma (UTUC) undergoing nephroureterectomy. MATERIALS AND
methodsWe retrospectively identified 107 UTUC patients who underwent nephroureterectomy between 2005 and 2020. DNA was extracted from FFPE specimens, and representative exons of FGFR3, KRAS, HRAS, and TP53 were analyzed by PCR followed by Sanger sequencing. Patients were classified into TP53, RAS, FGFR3, and triple-negative groups according to mutation status. Non-urothelial-tract recurrence-free survival (nutRFS) and overall survival (OS) were evaluated. To assess the incremental prognostic value of mutation-based classification beyond pathological information, parsimonious Cox models including pT, pN, and nuclear grade were constructed, and model discrimination was assessed using the concordance index.
resultsMutation status could not be fully determined in 17 patients; thus, 90 patients comprised the final cohort. Mutations in TP53, KRAS, HRAS, and FGFR3 were identified in 20 (22%), 4 (4%), 3 (3%), and 32 (36%) patients, respectively. In general, alterations in TP53, KRAS/HRAS, and FGFR3 were mutually exclusive. In exploratory multivariable analyses, the FGFR3 group showed more favorable nutRFS and OS than the TP53 group. Addition of mutation-based classification to a model including pT, pN, and nuclear grade modestly improved discrimination for nutRFS (c-index, 0.782 to 0.804) and OS (0.726 to 0.754).
conclusionsAlthough the improvement in discrimination was modest, a simplified mutation-based classification using archival FFPE specimens may provide additional prognostic information beyond pathological stage and contribute to postoperative risk stratification in UTUC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.